JP2005519961A - 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法 - Google Patents
継続的スルファターゼ阻害プロゲストゲンホルモン補充療法 Download PDFInfo
- Publication number
- JP2005519961A JP2005519961A JP2003575977A JP2003575977A JP2005519961A JP 2005519961 A JP2005519961 A JP 2005519961A JP 2003575977 A JP2003575977 A JP 2003575977A JP 2003575977 A JP2003575977 A JP 2003575977A JP 2005519961 A JP2005519961 A JP 2005519961A
- Authority
- JP
- Japan
- Prior art keywords
- estrogen
- effective
- hormone replacement
- progestogen
- continuous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000583 progesterone congener Substances 0.000 title claims abstract description 63
- 238000002657 hormone replacement therapy Methods 0.000 title claims abstract description 52
- 102000005262 Sulfatase Human genes 0.000 title claims abstract description 29
- 108060007951 sulfatase Proteins 0.000 title claims abstract description 29
- 239000000262 estrogen Substances 0.000 claims abstract description 80
- 229940011871 estrogen Drugs 0.000 claims abstract description 80
- 230000001681 protective effect Effects 0.000 claims abstract description 25
- 210000000481 breast Anatomy 0.000 claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 19
- 230000002950 deficient Effects 0.000 claims abstract description 16
- 230000003389 potentiating effect Effects 0.000 claims abstract description 16
- 230000002357 endometrial effect Effects 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 6
- 229940088597 hormone Drugs 0.000 claims description 25
- 239000005556 hormone Substances 0.000 claims description 25
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 claims description 12
- 239000006213 vaginal ring Substances 0.000 claims description 10
- 230000009245 menopause Effects 0.000 claims description 6
- 229940044953 vaginal ring Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000153 supplemental effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 51
- 206010006187 Breast cancer Diseases 0.000 description 42
- 208000026310 Breast neoplasm Diseases 0.000 description 42
- 230000000694 effects Effects 0.000 description 39
- 229960005309 estradiol Drugs 0.000 description 25
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 22
- 229960000417 norgestimate Drugs 0.000 description 22
- 150000003431 steroids Chemical class 0.000 description 18
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 14
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 14
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 13
- 229930182833 estradiol Natural products 0.000 description 13
- 229960003399 estrone Drugs 0.000 description 13
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000001839 systemic circulation Effects 0.000 description 8
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 6
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000007935 oral tablet Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 4
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 102100038021 Steryl-sulfatase Human genes 0.000 description 4
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 4
- 229960000766 danazol Drugs 0.000 description 4
- 108010005041 estrone sulfatase Proteins 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 102000014654 Aromatase Human genes 0.000 description 3
- 108010078554 Aromatase Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 olmeroxifene Chemical compound 0.000 description 3
- 102000003998 progesterone receptors Human genes 0.000 description 3
- 108090000468 progesterone receptors Proteins 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 3
- 229960001023 tibolone Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- ISHXLNHNDMZNMC-VTKCIJPMSA-N (3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C\1 ISHXLNHNDMZNMC-VTKCIJPMSA-N 0.000 description 2
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000252095 Congridae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- BVVFOLSZMQVDKV-KXQIQQEYSA-N ICI-164384 Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](CCCCCCCCCCC(=O)N(C)CCCC)CC3=CC(O)=CC=C3[C@H]21 BVVFOLSZMQVDKV-KXQIQQEYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940035811 conjugated estrogen Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960002667 norelgestromin Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 229960001584 promegestone Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- HJQQVNIORAQATK-DDJBQNAASA-N (e)-3-[4-[(z)-1,2-diphenylbut-1-enyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(\C=C\C(O)=O)=CC=1)/C1=CC=CC=C1 HJQQVNIORAQATK-DDJBQNAASA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- JICOGKJOQXTAIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol Chemical compound C=1C=C(OCCN2CCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 JICOGKJOQXTAIP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- NKZTZAQIKKGTDB-QPLCGJKRSA-N Fispemifene Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NFIXBCVWIPOYCD-UHFFFAOYSA-N N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-VEUSWCEHSA-N [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)[14CH]=C(O)C=C3 Chemical compound [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)[14CH]=C(O)C=C3 VOXZDWNPVJITMN-VEUSWCEHSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- YOQPCWIXYUNEET-UHFFFAOYSA-N chembl307697 Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O YOQPCWIXYUNEET-UHFFFAOYSA-N 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950007967 tesmilifene Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- RLQVKDVIBJCQGE-WDUCDQOOSA-N win-25540 Chemical compound O=C1C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 RLQVKDVIBJCQGE-WDUCDQOOSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Inhibition of Estrone Sulfatase Enzyme in Human Placenta and Human Breast Carcinoma;T.R.JEFFRY EVANSら、J.Steroid Biochem.Molec.Biol.Vol.39、No.4A 1991、pp.493−499 In Vitro Effect of Synthetic Progestogens on Estrone Sulfatase Activity in Human Breast Carcinoma;ODILE PROST−AVALLETら、J.Steroid Biochem.Molec.Biol.、Vol.39、No.6、1991、pp.967−973 Effect of the Progestagen Promegestone(R−5020)on mRNA of the Oestrone Sulfatase in the MCF−7 Human Mammary Cancer Cells;JORGE R.PASQUALINIら、Anticancer Research 14:1589−1594(1994) Effect of Nomegestrol Acetate on Estrone−sulfatase and 17β−Hydroxysteroid Dehydrogenase Activities in Human Breast Cancer Cells;G.CHETRITEら、J.Steroid Biochem.Molec.Biol.Vol.58、No.5/6、pp.525−531、1996 Effect of Tibolone(Org OD14)and its Metabolites on Estrone Sulfatase Activity in MCF−7 and T−47D Mammary Cancer Cells;G.CHETRITEら、Anticancer Research 17:135−140(1997) Progestins and Breast Cancer;J.R.PASQUALINIら、J.Steroid Biochem.Molec.Biol.Vol.65、No.1−6、pp.225−235、1998 Control of Estradiol In Human Breast Cancer.Effect Of Medrogestone on Sulfatase,17β−Hydroxysteroid Dehydrogenase And Sulfotransferase Activities in Human Breast Cancer Cells;JORGE RAUL PASQUALINIら、Euro.Congr.On Menopause(1998)、pp.625−633 Constitutive Expression of the Steroid Sulfatase Gene Supports theGrowth of MCF−7 Human Breast Cancer Cells in Vitro and in Vitro;MATTIE R.JAMESら、Endocrinology、Vol.142、No.4、pp 1497−1505 Concentrations of Estrone,Estradiol and Their Sulfates,And Evaluation of Sulfatase and Aromatase Activities in Patients with Breast Fibroadenoma;J.R.PASQUALINIら、Int.J.Cancer、70、pp.639−643(1997) Action of Danazol On The Conversion Of Estrone Sulfate To Estradiol And On The Sulfatase Activity In The MCF−7,T−47D and MDA−MB−231 Human Mammary Cancer Cells;B−L NGUYENら、J.Steroid Biochem,Molec.Biol.Vol.46、No.1、1993、pp.17−23 Effect of Promegstone,Tamoxifen,4−Hydroxytamoxifen and ICI 164,384 on the Oestrone Sulphatase Activity of Human Breast Cancer Cells;GERARD CHETRITEら、Anticancer Research 13:931−934(1993) Effect of the progestagen R5020(promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in MCF−7 and T−47d human mammary cancer cells:correlation with progesterone receptor levels;JORGE R.PASQUALINIら、Cancer Letters、66(1992)55−60、Elzevier Scientific Publishers Ireland Ltd Inhibition Of Steroid Sulfatase Activity By Danazol;KJELL CARLSTROMら、Acta Obstet Gynecol Scand Suppl.107−111
1.Inhibition of Estrone Sulfatase Enzyme in Human Placenta and Human Breast Carcinoma;T.R.JEFFRY EVANSら、J.Steroid Biochem.Molec.Biol.Vol.39、No.4A 1991、pp.493−499
2.In Vitro Effect of Synthetic Progestogens on Estrone Sulfatase Activity in Human Breast Carcinoma;ODILE PROST−AVALLETら、J.Steroid Biochem.Molec.Biol.、Vol.39、No.6、1991、pp.967−973
3.Effect of the progestagen R5020(promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in MCF−7 and T−47d human mammary cancer cells:correlation with progesterone receptor levels;JORGE R.PASQUALINIら、Cancer Letters、66(1992)55−60、Elzevier Scientific Publishers Ireland Ltd
4.Action of Danazol On The Conversion Of Estrone Sulfate To Estradiol And On The Sulfatase Activity In The MCF−7,T−47D and MDA−MB−231 Human Mammary Cancer Cells;B−L NGUYENら、J.Steroid Biochem,Molec.Biol.Vol.46、No.1、1993、pp.17−23
5.Effect of Promegstone,Tamoxifen,4−Hydroxytamoxifen and ICI 164,384 on the Oestrone Sulphatase Activity of Human Breast Cancer Cells;GERARD CHETRITEら、Anticancer Research 13:931−934(1993)
6.Inhibition Of Steroid Sulfatase Activity By Danazol;KJELL CARLSTROMら、Acta Obstet Gynecol Scand Suppl.107−111
7.Effect of the Progestagen Promegestone(R−5020)on mRNA of the Oestrone Sulfatase in the MCF−7 Human Mammary Cancer Cells;JORGE R.PASQUALINIら、Anticancer Research 14:1589−1594(1994)
8.Effect of Nomegestrol Acetate on Estrone−sulfatase and 17β−Hydroxysteroid Dehydrogenase Activities in Human Breast Cancer Cells;G.CHETRITEら、J.Steroid Biochem.Molec.Biol.Vol.58、No.5/6、pp.525−531、1996
9.Effect of Tibolone(Org OD14)and its Metabolites on Estrone Sulfatase Activity in MCF−7 and T−47D Mammary Cancer Cells;G.CHETRITEら、Anticancer Research 17:135−140(1997)
10.Progestins and Breast Cancer;J.R.PASQUALINIら、J.Steroid Biochem.Molec.Biol.Vol.65、No.1−6、pp.225−235、1998
11.Control of Estradiol In Human Breast Cancer.Effect Of Medrogestone on Sulfatase,17β−Hydroxysteroid Dehydrogenase And Sulfotransferase Activities in Human Breast Cancer Cells;JORGE RAUL PASQUALINIら、Euro.Congr.On Menopause(1998)、pp.625−633
12.Constitutive Expression of the Steroid Sulfatase Gene Supports theGrowth of MCF−7 Human Breast Cancer Cells in Vitro and in Vitro;MATTIE R.JAMESら、Endocrinology、Vol.142、No.4、pp1497−1505
13.Concentrations of Estrone, Estradiol and Their Sulfates,And Evaluation of Sulfatase and Aromatase Activities in Patients with Breast Fibroadenoma;J.R.PASQUALINIら、Int.J.Cancer、70、pp.639−643(1997)
[発明の詳細な説明]
本発明のHRTレジメンは、こうした治療の必要な閉経後もしくはエストロゲン欠乏の女性に、エストロゲンもしくはプロゲストゲンいずれかの投与の中断を伴わずに継続的に毎周期毎周期投与される。エストロゲン欠乏の女性は、天然のまたは化学的去勢、子宮および/もしくは卵巣の除去などのような人工的手段により早期にエストロゲン欠乏である女性を指すことを意図している。投与方法は経皮、膣もしくは経口であってよい。投与が経皮である場合、適する貼付剤を必要とされるように置換を伴い継続的に装用する。投与が膣である場合、リングのような適する膣装置を必要とされるように置換を伴い継続的に挿入する。投与が経口である場合、連日経口投薬ユニットを投与する。
化学物質
[6,7−3H(N)]−エストロンスルフェート(3H−E1S)、アンモニウム塩(比活性53Ci/mmol)および[4−14C]−エストラジオール(14C−E2)(比活性57mCi/mmol)はニュー イングランド ニュークリア ディビジョン(New England Nuclear Division)(DuPont de Nemours、Les Ulls、フランス)から購入した。放射性同位体の純度は使用前に適切な系での薄層クロマトグラフィー(TLC)により評価した。E1S、アンモニウム塩、未標識のE1およびE2(分析等級)はSigma−Aldrich Chimle(St Quentin Fallavier、フランス)から得た。17−デアセチルノルゲスチメート(NGMN;13−エチル−17−ヒドロキシ−18,19−ジノル−17α−プレグン−4−エン−20−イン−3−オンオキシム)はR.W.Johnson Pharmaceutical Research Institute、Medicinal Chemistry Department、(米国ニュージャージー州ラリタン)からの贈品であり;メドロキシプロゲステロンアセテート(MPA、17α−アセトキシ−6α−メチルプロゲステロン)はSigma−Aldrich Chimieから得た。全部の他の化学物質は商業的に入手可能な最高等級のものであった。
細胞培養
ホルモン依存性のMCF−7およびT−47Dヒト乳癌細胞株は、2mmol/l L−グルタミン、100U/ml ペニシリン−ストレプトマイシンおよびT−47Dについて5%ウシ胎児血清(FCS)(A.T.G.C.、Marne−la−Vallee、フランス)、もしくはMCF−7細胞について10%FCSを補充しかつ5%CO2の加湿雰囲気中37℃でインキュベートした、10mmol/l HEPES(pH7.6)で緩衝したイーグル最小必須培地(MEM)中で増殖させた。培地は週2回交換した。細胞は10〜12日ごとに継代し、そして3×106細胞/フラスコで75cm2フラスコ(A.T.G.C.)に再プレーティングした。実験の4日前に細胞を5%ステロイド枯渇処理したFCSを含有するMEMに移した。該FCSはデキストラン被覆炭(DCC)で4℃で一夜処理しておいた(0.1〜1%w/v、DCC−FCS)。本明細書で使用したMCF−7およびT−47D細胞株は、ブダペスト条約に従って、参照MCF7_JJPRDおよびT47D_JJPRDで2002年5月17日にThe Belgian Co−ordinated Collections of Microorganisms(BCCM)、Laboratorium voor Moleculaire Biologie、Universiteit Gent、K.L.Ledeganckstraat 35、B−9000、Gent、ベルギーに寄託され、そして、それぞれ受託番号LMBP 5862CBおよびLMBP 5863CBで公的に入手可能である。
[3H]−E1Sとともにインキュベートしたヒト乳癌細胞からの[3H]−エストラジオールの単離および定量
コンフルエント前の細胞を、単独で(対照細胞)または多様な化合物すなわち5×10−5〜5×10−9mol/lの濃度の範囲でエタノールに溶解した(最終濃度<0.2%)NGMNもしくはMPAとともに、5×10−9mol/lの[3H]−E1Sの添加を伴いMEM−DCC−FCS中37℃で4時間インキュベートした。対照細胞はエタノールベヒクルのみを受領した。24時間後に培地を除去し、細胞を氷冷ハンクス平衡塩類溶液(HBSS、カルシウム・マグネシウムを含まない)(A.T.G.C.)で2回洗浄し、そして掻き取りにより収集した。遠心分離後のペレットを80%エタノールで処理し、そして放射活性を−20℃で最低24時間抽出した。細胞の放射活性の取り込みをエタノール性上清中で測定し、また、残存するペレット中のDNA含量をBurton.Biochem Journal 62:315−323、1956に従って評価した。[14C]−E2(5,000dpm)を添加して分析による喪失をモニターし、また、未標識のE1およびE2(50μg)を担体および参照指標として使用した。全エタノール抽出物中で、クロロホルム−酢酸エチル(4:1、v/v)系で展開するシリカゲル60F254(Merck、Darmstadt、ドイツ)上での薄層クロマトグラフィー(TLC)によりE2を単離した。254nmのU.V.下でのエストロゲンの可視化後に適切な領域を小片に切断し、エタノール(0.5ml)を含む液体シンチレーションバイアルに入れ、そして30分間抽出させた。3mlのOpti−fluor(Packard、Rungis、フランス)を添加し、そしてバイアルを外的標準化によるクエンチ補正を用いて3Hおよび14C含量について分析した。E2の量的評価は細胞に関連した全放射活性のパーセントとして計算し、そしてその後E1Sからの形成されたE2/mg DNAのfmolとして表した。
統計学的解析
データは平均±平均の標準誤差(SEM)値として表す。スチューデントのt検定を使用して平均間の差違の有意性を評価し;≦0.05のp値を有意とみなした。
結果
表3はホルモン依存性ヒト乳癌細胞株T−47DにおけるE1SのE2への転化に対するNGMNおよびメドロキシプロゲステロンアセテート(MPA)濃度の影響を示す。データは3回の独立した実験の二重の測定値の平均±SEMである。*対照値(未処理細胞)に対しp≦0.05;**対照値(未処理細胞)に対しp≦0.005
Claims (5)
- 有効なホルモン補充量のエストロゲン、ならびに有効な子宮内膜保護量および有効な***保護量の双方である量の強力なスルファターゼ阻害プロゲストゲンであるプロゲストゲンの組合せを、ホルモン補充療法の必要な閉経後もしくはエストロゲン欠乏の女性に継続投与する段階を含んでなる、ホルモン補充療法の方法。
- 一周期の期間の間の連続的な連日経口投与に適合された一周期の個別の投薬ユニットを含んでなり、前記投薬ユニットが、製薬学的に許容できる担体との混合状態で、有効なホルモン補充量のエストロゲン、ならびに有効な子宮内膜保護量および有効な***保護量の双方である量の強力なスルファターゼ阻害プロゲストゲンであるプロゲストゲンの組合せを含有する、ホルモン補充療法の必要な閉経後もしくはエストロゲン欠乏の女性への投与のための継続的ホルモン補充治療ユニット。
- 一周期の期間の間の連続的投与に適合された1個もしくはそれ以上の経皮貼付剤を含んでなり、治療ユニットの前記経皮貼付剤が、一周期の継続投与のための、有効なホルモン補充量のエストロゲンならびに有効な子宮内膜保護量および有効な***保護量の双方である量の強力なスルファターゼ阻害プロゲストゲンであるプロゲストゲンの組合せを集合的に含有する、ホルモン補充療法の必要な閉経後もしくはエストロゲン欠乏の女性への投与のための継続的ホルモン補充治療ユニット。
- 一周期の期間の間の連続的投与に適合された1個もしくはそれ以上の膣リングを含んでなり、治療ユニットの前記膣リングが、一周期の継続投与のための、有効なホルモン補充量のエストロゲンならびに有効な子宮内膜保護量および有効な***保護量の双方である量の強力なスルファターゼ阻害プロゲストゲンであるプロゲストゲンの組合せを集合的に含有する、ホルモン補充療法の必要な閉経後もしくはエストロゲン欠乏の女性への投与のための継続的ホルモン補充治療ユニット。
- 一周期の期間の間の連続的な連日経口投与に適合された一周期の個別の投薬ユニットを含んでなり、前記投薬ユニットが、製薬学的に許容できる担体との混合状態で、有効なホルモン補充量のエストロゲンと組合せで使用された場合に有効な子宮内膜保護量および有効な***保護量の双方である量の強力なスルファターゼ阻害プロゲストゲンとなるプロゲストゲンを含有する、ホルモン補充療法の必要な閉経後もしくはエストロゲン欠乏の女性への投与のための継続的ホルモン補充治療ユニット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36314802P | 2002-03-11 | 2002-03-11 | |
US38154102P | 2002-05-17 | 2002-05-17 | |
PCT/US2003/007452 WO2003077924A1 (en) | 2002-03-11 | 2003-03-11 | Continuous sulfatase inhibiting progestogen hormone replacement therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005519961A true JP2005519961A (ja) | 2005-07-07 |
Family
ID=28045285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003575977A Pending JP2005519961A (ja) | 2002-03-11 | 2003-03-11 | 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20030229057A1 (ja) |
EP (1) | EP1482948B1 (ja) |
JP (1) | JP2005519961A (ja) |
CN (1) | CN1652798A (ja) |
AT (1) | ATE336252T1 (ja) |
AU (1) | AU2003220171A1 (ja) |
CA (1) | CA2478194A1 (ja) |
CY (1) | CY1105646T1 (ja) |
DE (1) | DE60307602T2 (ja) |
DK (1) | DK1482948T3 (ja) |
ES (1) | ES2269999T3 (ja) |
HK (1) | HK1070003A1 (ja) |
PT (1) | PT1482948E (ja) |
WO (1) | WO2003077924A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
EP1453521B1 (en) * | 2001-12-05 | 2013-09-04 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
EP1624848A4 (en) * | 2003-05-02 | 2009-02-25 | Duramed Pharmaceuticals Inc | METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE |
US7816546B2 (en) * | 2003-06-30 | 2010-10-19 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime |
ZA200600201B (en) * | 2003-07-16 | 2008-07-30 | Duramed Pharmaceuticals Inc | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
EP1761231A1 (en) * | 2004-06-07 | 2007-03-14 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of dub |
US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
US20070077269A1 (en) * | 2005-10-04 | 2007-04-05 | Woodward John R | Method of birth control and hormone regulation |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01132523A (ja) * | 1987-09-24 | 1989-05-25 | Jencap Res Ltd | ホルモン製剤及び方法 |
WO1989005663A1 (en) * | 1986-12-29 | 1989-06-29 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
JPH11501323A (ja) * | 1995-06-07 | 1999-02-02 | シグナス,インコーポレイテッド | 17−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法 |
WO2000059577A1 (en) * | 1999-03-30 | 2000-10-12 | Jencap Research Ltd. | Low dose estrogen interrupted hormone replacement therapy |
US6165491A (en) * | 1998-04-27 | 2000-12-26 | Effik Sca Bat | Pharmaceutical composition based on estrogen and progesterone |
JP2001505930A (ja) * | 1997-10-16 | 2001-05-08 | マクロケム・コーポレーシヨン | 皮膚への局所的施用のためのホルモン代償療法薬剤 |
WO2001052857A1 (en) * | 2000-01-18 | 2001-07-26 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3545397A (en) * | 1969-03-17 | 1970-12-08 | Dowty Technical Dev Ltd | Air-cushion vehicles and like craft |
IL48277A (en) * | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
US4292965A (en) * | 1978-12-29 | 1981-10-06 | The Population Council, Inc. | Intravaginal ring |
SE8602666D0 (sv) * | 1986-06-16 | 1986-06-16 | Leo Ab | Intravaginal devices |
US5188835A (en) * | 1986-06-16 | 1993-02-23 | Kabi Pharmacia Ab | Intravaginal devices |
US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US5006342A (en) * | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
US4906169A (en) * | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5422119A (en) * | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
-
2003
- 2003-03-11 PT PT03716467T patent/PT1482948E/pt unknown
- 2003-03-11 DK DK03716467T patent/DK1482948T3/da active
- 2003-03-11 AT AT03716467T patent/ATE336252T1/de active
- 2003-03-11 AU AU2003220171A patent/AU2003220171A1/en not_active Abandoned
- 2003-03-11 WO PCT/US2003/007452 patent/WO2003077924A1/en active IP Right Grant
- 2003-03-11 ES ES03716467T patent/ES2269999T3/es not_active Expired - Lifetime
- 2003-03-11 CN CNA03810718XA patent/CN1652798A/zh active Pending
- 2003-03-11 DE DE60307602T patent/DE60307602T2/de not_active Expired - Lifetime
- 2003-03-11 US US10/385,594 patent/US20030229057A1/en not_active Abandoned
- 2003-03-11 JP JP2003575977A patent/JP2005519961A/ja active Pending
- 2003-03-11 EP EP03716467A patent/EP1482948B1/en not_active Expired - Lifetime
- 2003-03-11 CA CA002478194A patent/CA2478194A1/en not_active Abandoned
-
2005
- 2005-04-06 HK HK05102864A patent/HK1070003A1/xx not_active IP Right Cessation
-
2006
- 2006-10-04 CY CY20061101435T patent/CY1105646T1/el unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989005663A1 (en) * | 1986-12-29 | 1989-06-29 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
JPH01132523A (ja) * | 1987-09-24 | 1989-05-25 | Jencap Res Ltd | ホルモン製剤及び方法 |
JPH11501323A (ja) * | 1995-06-07 | 1999-02-02 | シグナス,インコーポレイテッド | 17−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法 |
JP2001505930A (ja) * | 1997-10-16 | 2001-05-08 | マクロケム・コーポレーシヨン | 皮膚への局所的施用のためのホルモン代償療法薬剤 |
US6165491A (en) * | 1998-04-27 | 2000-12-26 | Effik Sca Bat | Pharmaceutical composition based on estrogen and progesterone |
WO2000059577A1 (en) * | 1999-03-30 | 2000-10-12 | Jencap Research Ltd. | Low dose estrogen interrupted hormone replacement therapy |
WO2001052857A1 (en) * | 2000-01-18 | 2001-07-26 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
Also Published As
Publication number | Publication date |
---|---|
ES2269999T3 (es) | 2007-04-01 |
DE60307602D1 (de) | 2006-09-28 |
EP1482948B1 (en) | 2006-08-16 |
CA2478194A1 (en) | 2003-09-25 |
CY1105646T1 (el) | 2010-12-22 |
WO2003077924A1 (en) | 2003-09-25 |
ATE336252T1 (de) | 2006-09-15 |
CN1652798A (zh) | 2005-08-10 |
PT1482948E (pt) | 2006-11-30 |
AU2003220171A1 (en) | 2003-09-29 |
EP1482948A1 (en) | 2004-12-08 |
HK1070003A1 (en) | 2005-06-10 |
DE60307602T2 (de) | 2007-10-04 |
DK1482948T3 (da) | 2006-11-27 |
US20030229057A1 (en) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005519961A (ja) | 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法 | |
JP2005519962A (ja) | スルファターゼを阻害する継続的プロゲストゲン避妊レジメン | |
US20150359802A1 (en) | Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis | |
JP2005519964A (ja) | スルファターゼ阻害プロゲストゲンのみの避妊レジメン | |
CN101626760A (zh) | 利用递增剂量长周期给药方案进行激素治疗的方法 | |
Goletiani et al. | Progesterone: review of safety for clinical studies. | |
US20030191096A1 (en) | Method of hormonal therapy | |
US20040142914A1 (en) | Extended transdermal contraceptive regimens | |
US20030219471A1 (en) | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens | |
JP2005519963A (ja) | 長期サイクルのエストロゲンおよびスルファターゼ阻害プロゲストゲン避妊レジメン | |
HRP20020666A2 (en) | Drospirenone for hormone replacement therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060313 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091021 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091028 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100330 |